IL17A and ankylosing spondylitis: Since mutations of IL‐23 receptor have been associated with the development of ankylosing spondylitis in humans, we wanted to examine whether loss of IL‐23 or IL‐17 would also decrease the severity of arthritis and the inflammation of the heart valves in BPSM1 mice.